Not only specific KRAS mutations could influence the pathological nature of cancer or its therapeutic response, but also the co-occurrence and correlation of other driver mutations with KRAS could significantly influence OS, PFS, or disease recurrence and therapeutic management. This evidence concerns the gene KRAS and cancer.